# KPV gut inflammation: PepT1 Uptake and Colitis Research — KPV peptide > KPV gut inflammation research: how the KPV peptide enters inflamed gut cells via PepT1 and reduced colitis severity in DSS and TNBS mouse models. The IBD evidence base, cited to source. The gut is where the KPV literature is deepest. Here is the transporter, the colitis models, and the mucosal-barrier work — and the line where the human data stop. ## In plain English This page covers the KPV gut inflammation research — the part of the literature where the most is known. The gut lining gets inflamed in conditions like inflammatory bowel disease. KPV is interesting here for a neat reason: a transporter in the gut wall called PepT1 grabs small peptides and pulls them inside, and that transporter becomes more active exactly where the gut is inflamed. So KPV tends to be drawn into the cells that need calming most. In mice with chemically-induced colitis, oral KPV lowered how severe the inflammation got. Said plainly: this is strong mouse and cell evidence, not a human treatment. There is no human trial of KPV for any gut condition. ## PepT1: The Transporter That Concentrates KPV Where It's Needed The mechanism that makes KPV a gut candidate is its route of entry. PepT1 (SLC15A1) is a di/tripeptide transporter — a channel in the gut lining that carries small peptides into epithelial cells — and its expression is upregulated in inflamed intestinal tissue. Dalmasso and colleagues demonstrated that KPV enters human intestinal epithelial cells and immune cells through PepT1, and that nanomolar KPV (~10 nM) suppressed NF-kB and MAP-kinase activation and reduced pro-inflammatory cytokine secretion [1]. The consequence is a built-in targeting effect: because PepT1 rises in inflamed mucosa, the inflamed regions take up proportionally more peptide. That observation is what later motivated PepT1-targeted nanoparticle and nanodrug designs, which aim to ride the same transporter to deliver KPV selectively to inflamed colon [5] [12]. ## KPV in Murine Colitis Models (DSS and TNBS) ### KPV colitis evidence in DSS and TNBS models The KPV colitis evidence rests on two standard chemical models of inflammatory bowel disease. DSS (dextran sodium sulfate) colitis and TNBS (trinitrobenzene sulfonic acid) colitis are induced chemically in mice and used to test anti-inflammatory candidates. Oral KPV in drinking water (~100 uM) reduced the severity of both DSS- and TNBS-induced colitis [1]. A dedicated inflammatory-bowel-disease study added outcome detail. In the DSS model, KPV-treated mice showed earlier recovery and significantly stronger regain of body weight, with reduced colonic inflammatory infiltrate and lower myeloperoxidase (MPO) activity — MPO being a neutrophil enzyme used as a tissue marker of inflammatory infiltration. Critically, the benefit persisted in MC1R-deficient mice, indicating the effect is melanocortin-receptor-independent [2]. Together these establish a reproducible reduction in colitis severity across models and readouts. ## Mucosal Barrier and Tight Junctions: Restoring the Gut Lining Beyond damping signals, recent work measures structural repair. The mucosal barrier — the epithelial lining and its tight-junction network — is what keeps gut contents from leaking into tissue, and tight-junction restoration is a key outcome in KPV gut studies. Orally targeted hyaluronic-acid-functionalized KPV nanoparticles in a chitosan/alginate hydrogel prevented mucosal damage and downregulated TNF-alpha more effectively than non-targeted delivery, accelerating mucosal healing in DSS colitis [5]. The 2024 PepT1-targeted nanodrug pushed this further: co-assembling KPV with the immunosuppressant FK506 improved both acute and chronic DSS colitis, specifically restoring tight-junction proteins and lowering inflammatory cytokines more than either agent alone [12]. A self-cross-linked cysteamine-grafted gamma-polyglutamic-acid hydrogel was likewise built to stabilize KPV for inflammatory-bowel-disease delivery [9]. ## What is KPV used for? Its most-studied research use is intestinal inflammation: KPV is taken up by PepT1 in inflamed gut epithelium and reduced colitis severity in mouse models [1] [2]. It is not an approved therapy and has no human efficacy data, so "used for" here means "studied in," not "prescribed for." ## How does KPV reduce inflammation? It suppresses NF-kB nuclear translocation and MAP-kinase signaling and reduces pro-inflammatory cytokine secretion [1]. In the gut it enters epithelial cells via the PepT1 transporter, which is upregulated in inflamed tissue, so the inflamed regions take up more peptide [1]. Its action appears largely melanocortin-receptor-independent [2] [3]. ## The Honest Limit: No Human Gut-Inflammation Trials Every result above is preclinical. The KPV gut-inflammation literature is built from human cell lines, mouse colitis models, and materials chemistry — there are no published human clinical trials of KPV for inflammatory bowel disease or any other indication, and no validated human dose [14]. Marketing that presents KPV as a finished gut-health solution outruns the evidence, which is mechanistic and preclinical rather than clinical. For the regulatory standing and how lawful compounded-peptide access actually works, see [KPV legal status and compounding access](/legal-status). --- A neon-grid research console reading the KPV record straight — the three-bead Lys-Pro-Val chain traced from PepT1 uptake to NF-kB suppression and logged to its studies, the empty human-trial line and the FDA-under-review standing left lit in plain sight; no clinic behind the grid and nothing here dispensed or sold.